1887

Abstract

A universal influenza vaccine that does not require annual reformulation would have clear advantages over the currently approved seasonal vaccine. In this study, we combined the mucosal adjuvant alpha-galactosylceramide (αGalCer) and peptides designed across the highly conserved influenza precursor haemagglutinin (HA) cleavage loop as a vaccine. Peptides designed across the HA of influenza A/H3N2 viruses, delivered to mice via the intranasal route with αGalCer as an adjuvant, provided 100 % protection following H3N2 virus challenge. Similarly, intranasal inoculation of peptides across the HA of influenza A/H5N1 with αGalCer completely protected mice against heterotypic challenge with H3N2 virus. Our data suggest that these peptide vaccines effectively inhibited subsequent influenza A/H3N2 virus replication. In contrast, only 20 % of mice vaccinated with αGalCer-adjuvanted peptides spanning the HA of H5N1 survived homologous viral challenge, possibly because the HA of this virus subtype is cleaved by intracellular furin-like enzymes. Results of these studies demonstrated that HA peptides adjuvanted with αGalCer have the potential to form the basis of a synthetic, intranasal influenza vaccine.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.028985-0
2011-05-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/92/5/1152.html?itemId=/content/journal/jgv/10.1099/vir.0.028985-0&mimeType=html&fmt=ahah

References

  1. Alsharifi M., Furuya Y., Bowden T. R., Lobigs M., Koskinen A., Regner M., Trinidad L., Boyle D. B., Müllbacher A. 2009; Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS ONE 4:e5336 [View Article][PubMed]
    [Google Scholar]
  2. Au-Yeung B. B., Fowell D. J. 2007; A key role for Itk in both IFN gamma and IL-4 production by NKT cells. J Immunol 179:111–119[PubMed] [CrossRef]
    [Google Scholar]
  3. Bendelac A., Rivera M. N., Park S. H., Roark J. H. 1997; Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15:535–562 [View Article][PubMed]
    [Google Scholar]
  4. Bianchi E., Liang X., Ingallinella P., Finotto M., Chastain M. A., Fan J., Fu T. M., Song H. C., Horton M. S. et al. 2005; Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol 79:7380–7388 [View Article][PubMed]
    [Google Scholar]
  5. Borg N. A., Wun K. S., Kjer-Nielsen L., Wilce M. C., Pellicci D. G., Koh R., Besra G. S., Bharadwaj M., Godfrey D. I. et al. 2007; CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448:44–49 [View Article][PubMed]
    [Google Scholar]
  6. Brossay L., Jullien D., Cardell S., Sydora B. C., Burdin N., Modlin R. L., Kronenberg M. 1997; Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol 159:1216–1224[PubMed]
    [Google Scholar]
  7. Chen J., Lee K. H., Steinhauer D. A., Stevens D. J., Skehel J. J., Wiley D. C. 1998; Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95:409–417 [View Article][PubMed]
    [Google Scholar]
  8. Danke N. A., Kwok W. W. 2003; HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J Immunol 171:3163–3169[PubMed] [CrossRef]
    [Google Scholar]
  9. Du W., Gervay-Hague J. 2005; Efficient synthesis of alpha-galactosyl ceramide analogues using glycosyl iodide donors. Org Lett 7:2063–2065 [View Article][PubMed]
    [Google Scholar]
  10. Gazit R., Gruda R., Elboim M., Arnon T. I., Katz G., Achdout H., Hanna J., Qimron U., Landau G. et al. 2006; Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 7:517–523 [View Article][PubMed]
    [Google Scholar]
  11. Gebe J. A., Novak E. J., Kwok W. W., Farr A. G., Nepom G. T., Buckner J. H. 2001; T cell selection and differential activation on structurally related HLA-DR4 ligands. J Immunol 167:3250–3256[PubMed] [CrossRef]
    [Google Scholar]
  12. Horváth A., Tóth G. K., Gogolák P., Nagy Z., Kurucz I., Pecht I., Rajnavölgyi E. 1998; A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol Lett 60:127–136 [View Article][PubMed]
    [Google Scholar]
  13. Huber V. C., Lynch J. M., Bucher D. J., Le J., Metzger D. W. 2001; Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166:7381–7388[PubMed] [CrossRef]
    [Google Scholar]
  14. Klenk H. D., Rott R., Orlich M., Blödorn J. 1975; Activation of influenza A viruses by trypsin treatment. Virology 68:426–439 [View Article][PubMed]
    [Google Scholar]
  15. Ko S. Y., Ko H. J., Chang W. S., Park S. H., Kweon M. N., Kang C. Y. 2005; α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175:3309–3317[PubMed] [CrossRef]
    [Google Scholar]
  16. Kok T., Mickan L. D., Burrell C. J. 1994; Routine diagnosis of seven respiratory viruses and Mycoplasma pneumoniae by enzyme immunoassay. J Virol Methods 50:87–100 [View Article][PubMed]
    [Google Scholar]
  17. Lazarowitz S. G., Choppin P. W. 1975; Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 68:440–454 [View Article][PubMed]
    [Google Scholar]
  18. Lennette, E. H. & Schmidt, N. J. (1979 Diagnostic Procedures for: Viral, Rickettsial and Chlamydial Infections. Washington, DC 20005: American Public Health Association, Inc.
  19. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., Abraham R., Juji T., Macfarlane D. J., Nicol A. J. 2004; Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383–389 [View Article][PubMed]
    [Google Scholar]
  20. Nishimura H., Itamura S., Iwasaki T., Kurata T., Tashiro M. 2000; Characterization of human influenza A (H5N1) virus infection in mice: neuro-, pneumo- and adipotropic infection. J Gen Virol 81:2503–2510[PubMed]
    [Google Scholar]
  21. Renegar K. B., Small P. A. Jr 1991; Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146:1972–1978[PubMed]
    [Google Scholar]
  22. Renegar K. B., Small P. A. Jr, Boykins L. G., Wright P. F. 2004; Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978–1986[PubMed] [CrossRef]
    [Google Scholar]
  23. Slingluff C. L. Jr, Yamshchikov G., Neese P., Galavotti H., Eastham S., Engelhard V. H., Kittlesen D., Deacon D., Hibbitts S. et al. 2001; Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7:3012–3024[PubMed]
    [Google Scholar]
  24. Stone B., Burrows J., Schepetiuk S., Higgins G., Hampson A., Shaw R., Kok T. 2004; Rapid detection and simultaneous subtype differentiation of influenza A viruses by real time PCR. J Virol Methods 117:103–112 [View Article][PubMed]
    [Google Scholar]
  25. Tam J. P. 1994; Immunization with peptide-carrier complexes: traditional and multiple-antigen peptide systems. In Peptide Antigens, a Practical Approach pp. 83–115 Edited by Wisdom G. B. Oxford: IRL Press;
    [Google Scholar]
  26. Thomas P. G., Keating R., Hulse-Post D. J., Doherty P. C. 2006; Cell-mediated protection in influenza infection. Emerg Infect Dis 12:48–54[PubMed] [CrossRef]
    [Google Scholar]
  27. Treanor J. 2004; Influenza vaccine–outmaneuvering antigenic shift and drift. N Engl J Med 350:218–220 [View Article][PubMed]
    [Google Scholar]
  28. Veldt B. J., van der Vliet H. J., von Blomberg B. M., van Vlierberghe H., Gerken G., Nishi N., Hayashi K., Scheper R. J., de Knegt R. J., Vandeneertwegh A. 2007; Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 47:356–365 [View Article][PubMed]
    [Google Scholar]
  29. Wilson I. A., Cox N. J. 1990; Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 8:737–787 [View Article][PubMed]
    [Google Scholar]
  30. Yen H. L., Monto A. S., Webster R. G., Govorkova E. A. 2005; Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192:665–672 [View Article][PubMed]
    [Google Scholar]
  31. Youn H. J., Ko S. Y., Lee K. A., Ko H. J., Lee Y. S., Fujihashi K., Boyaka P. N., Kim S. H., Horimoto T., Kweon M. 2007; A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25:5189–5198 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.028985-0
Loading
/content/journal/jgv/10.1099/vir.0.028985-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error